Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 466

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 466
---
 of the Mergers:

|                                                                       |     | Common Shares Issued or 
 Assumed to be Issued    |            |
| TuHURA Biosciences, Inc. weighted average shares after Kintara Merger |     |                         | 42,284,525 |
| Shares issued as purchase consideration in Mergers                    |     |                         |  3,998,054 |
| Shares issued in connection with the June 2025 Private Placement      |     |                         |  4,759,309 |
| Shares issued for TuHURA Warrant and Option Exercises(1)              |     |                         |  1,398,177 |
| Shares underlying Penny Warrants issued(2)                            |     |                         |    297,029 |
| Pro Forma weighted average shares outstanding                         |     |                         | 52,737,094 |

| (1) | The aggregate amount of shares issued in connection with TuHURA Warrants and stock options that have been exercised following the closing of the Kintara Merger through the closing date of the Mergers. |

| (2) | Penny Warrants assumed to be exercised and converted into shares of TuHURA Common Stock as soon as they were exercisable based on the nominal exercise price of $0.01 per share |

F-197

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Net loss per share to give pro forma effect of both the Kintara Merger as well as the Mergers was calculated using the weighted average shares outstanding as calculated following the consummation of the Kintara Merger, and the issuance of additional shares in connection with the Mergers, assuming the shares were outstanding since January 1, 2024. As the Transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Transactions have been outstanding for the entirety of all periods presented. The unaudited pro forma condensed combined financial information has been prepared to present the Mergers for the year ended December 31, 2024 and the six months ended June 30, 2025:

| Numerator:                                                                           |     | For the Year Ended    
 December 31, 2024 (1) |             |   |     | For the Six Months      
 Ended June 30, 2025 (